Enorama Pharma AB (publ) filed its Annual on Apr 13, 2022 for the period ending Dec 31, 2021. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.43 SEK | -5.45% | 0.00% | -21.61% |
05-22 | Enorama Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
02-28 | Intervacc's Acting CEO Assumes Role Permanently | MT |
1st Jan change | Capi. | |
---|---|---|
-21.61% | 9.43M | |
+16.50% | 42.12B | |
+20.78% | 21.72B | |
+21.14% | 15.75B | |
+23.69% | 14.89B | |
+57.44% | 13.06B | |
-0.05% | 6.79B | |
-14.94% | 6.3B | |
+20.03% | 6.05B | |
-8.87% | 5.73B |
- Stock Market
- Equities
- ERMA Stock
- News Enorama Pharma AB
- Enorama Pharma AB Auditor Raises 'Going Concern' Doubt